Introduction
An emerging class of drugs that allosterically modulate enzymatic activity is generating considerable excitement because of the many reported advantages associated with this approach for the treatment of metabolic diseases [1] [2] [3] [4] [5] [6] . Safety of traditional competitive inhibitor drugs is always an issue, since when present in excessive amounts, they can result in an overdose.
Allosteric drugs have an important advantage over competitive inhibitor drugs because once an allosteric drug reaches sufficient concentration to saturate the effector binding site, higher concentrations do not cause additional regulatory effects. Another related advantage is that the extent of the allosteric effect can be moderated based on drug chemistry design 5, 7 . However, despite the promise of the allosteric drug approach, methods to verify that an allosteric response, demonstrated in vitro, modifies a disease state in vivo are lacking. In vivo model systems are needed to verify outcomes of targeting allosteric regulation before committing to the cost of allosteric drug development.
To truly appreciate the need for in vivo verification of allosteric drug targets, consider the following scenario. Cell culture or animal studies demonstrate that a given protein is a potential contributor to an observed phenotype. A literature review indicates an allosteric regulation for the identified protein in the context of a signal transduction pathway. Unfortunately, allostery for the isolated protein was characterized at 20°C, pH 8.2, in a very low protein context, and in a hypertonic-Na + /buffer solution, an environment which fails to recapitulate in vivo physiology. pH, salt concentration, temperature, and other conditions used for these in vitro evaluations are usually selected based on the set of parameters that results in the largest detectable allosteric response.
Test tube conditions may be quite arbitrary relative to cellular environments, where the extent of allosteric regulation is dependent on pH 8 , salt type and concentration 9 , and temperature 10, 11 . The challenges are to accurately incorporate in vitro observations to explain in vivo outcomes and evaluate test-tube allostery as a relevant regulation that can be modified to treat disease. These in vitro/in vivo correlation deficiencies are particularly problematic in efforts to rationally design allosteric drugs. Thus, we propose to introduce mutations that mimic allosteric regulation by genome-editing into cell or animal models to verify allosteric drug targets in vivo. In this study, we focus on "allosterically engineering" human liver pyruvate kinase (LPYK for liver PYK and hLPYK for the human isozyme) to demonstrate that mutations can mimic allosteric outcomes in vivo, the first step needed in our proposed model system design. In a healthy individual, these regulatory mechanisms result in tight control of PYK activity in the liver. This control is critical since 90% of blood glucose produced by gluconeogenesis is generated in the liver. For the treatment of hyperglycemia, these regulatory mechanisms offer a variety of potential targets for rational drug design aimed at increasing hLPYK activity, either through activation or preventing inhibition, and therefore increasing hepatic glycolysis. More specifically, we anticipate that activation of liver pyruvate kinase under conditions that favor hepatic gluconeogenesis, such as occurs in the diabetic liver, will create a futile cycle that will waste energy and reduce/prevent hepatic production of glucose ( Figure 1 ).
Materials and Methods
All methods were performed in accordance with relevant guidelines. This includes animal studies, which were performed according to NIH guidelines. 
In vitro characterizations of mutant hLPYK
All protein purification and enzyme assay methods have been previously described 12 .
Mutagenesis of the human l/r-pyk gene was performed with a QuikChange kit (Stratagene).
Proteins were expressed in the FF50 strain of Escherichia coli 8 that has both native E. coli PYK genes deleted. Mutant proteins were partially purified using ammonium sulfate fractionation followed by dialysis 13 . Activity measurements were at 30ºC, using a lactate dehydrogenase coupled assay in HEPES buffer, pH 7.5 9 . Titrations of activity with a range of concentrations of PEP were used to evaluate Kapp-PEP (the PEP concentration at half Vmax) and that Kapp-PEP value was determined over a concentration range of effector (i.e., Fru-1,6-BP or alanine) to evaluate allosteric coupling.
Transgene design
A transgene was constructed using standard molecular biology procedures. , and S12A mutations were introduced into the transgene construct as described above. The transgene cassette was isolated for microinjection by restriction enzyme digestion and agarose gel purification.
This transgene cassette was microinjected into the pronuclei of fertilized mouse C57BL/6 oocytes and transgenic mice were obtained, following protocols utilized by the KUMC Transgenic and Gene Targeting Institutional Facility. Germline transmission and transgene lethality were tested by crossing founder male transgenic animals with C57BL/6 females. Due to the constitutively activated design of the transgene, no effort was made to alter the native copy of the mouse Pyklr gene. The influence on metabolism we were most interested in is the condition in which wild-type mouse LPYK produced from the native Pyklr mouse gene is inhibited, but the hLPYK protein produced from the transgene would remain activated. As noted below, the potential of hybrid LPYK tetramers undermines these considerations and, therefore, the use of the transgenic mouse created in this study was limited to confirming that expression of the triple mutant hLPYK is not lethal.
Mass spectrometry detection of modified hLPYK expression
Livers from wild-type and transgenic mice were extracted and liver tissue was homogenized with a hand-held ground-glass homogenizer. Samples were filtered through four layers of cheesecloth. Western blot analysis using a polyclonal goat anti-LPYK antibody (a gift from Dr. James Blair) did not reveal any differences in protein expression level. 
Results
The site of phosphorylation and locations of ligand binding sites have been mapped onto the structure of PYK 5, 17, [19] [20] [21] [22] [23] [24] [25] [26] . In previous studies, we used knowledge of these locations to introduce a series of mutations into each regulatory site 12, 13, 27 . Those mutation series empirically identified mutations that both increase and decrease allosteric responses (Figure 1 ). However, for use in in vivo studies for drug development, it will be important for mutations to influence only the targeted allosteric functions without causing global changes to all enzyme functions.
Therefore, in this study we extended the characterization of previously identified mutations to ensure that each mutation influences only a single regulatory property of the enzyme. We also extended the study by combining three mutations that promote more activity for both an in vitro characterization of protein regulation and an in vivo test to confirm that expression of the constitutively active enzyme is not lethal in mice.
H476L, S531E, and S12A mutations all convert the enzyme towards a more activated/less inhibited form that is, the enzyme binds PEP with a higher affinity 12, 13, 27 . H476L causes a complete loss of response to the allosteric inhibitor alanine. Based on previous data 7 , this lack of response is likely due to the inability of the H476L mutant protein to bind alanine or any other regulatory amino acid. However, without direct information on alanine binding to the protein, a lack of response to an effector does not distinguish whether the effector fails to bind to the mutant protein or if the effector binds, but does not elicit an allosteric response. The H476L mutation in the amino acid effector binding site does not influence PEP affinity in the absence of effectors (left y-intercept in graphs of Figure 2 ) or modify the response of the enzyme to Fru-1,6-BP activation.
S531E adds a negative charge to a loop within the Fru-1,6-BP binding site that is critical for allosteric activation. The added charge largely mimics activation by Fru-1,6-BP; that is, PEP affinity in the mutant protein is increased to close to the same affinity as is observed for the wildtype hLPYK protein when Fru-1,6-BP is bound. Furthermore, the addition of Fru-1,6-BP caused only a slight additional increase in PEP affinity. The S531E does not completely activate the enzyme to the same level as Fru-1,6-BP. However, our laboratory has now characterized more than 800 mutations of l/r-pyk 12, 27, 28 . Using these mutations as a point-of-comparison, the response of S531E is a good mimic of Fru-1,6-BP activation. The S531E mutant protein also retains the response to alanine, although that response ( Figure 2 , the distance between the plateaus at low and high alanine concentrations) is slightly increased compared to the wild-type enzyme.
The S12A mutation removes the side-chain hydroxyl group of Ser12 that is phosphorylated by cyclic-AMP dependent protein kinase in response to hormone signals 13 . Although this mutation also slightly reduces PEP affinity (left y-intercept of Figure 2 ) compared to the-wildtype enzyme, increased PEP affinity influences the enzyme in the same direction as our global goal of a more active enzyme. The S12A enzyme retains qualitative responses to both alanine and
Fru-1,6-BP. Quantitatively, the allosteric response ( Figure 2 , the distance between the plateaus at low and the high effector concentration) to alanine is similar to that of the wild-type enzyme. The allosteric response to Fru-1,6-BP is reduced compared to the wild-type protein due to the slightly reduced PEP affinity in the absence of effector. Nonetheless, the affinity of S12A for PEP in the presence of saturating concentrations of Fru-1,6-BP is similar to the wild-type protein.
Although our main interest is activation of hLPYK, there may be reasons to allosterically engineer this protein for inhibition. N82A, R501V, and S12D are three mutations in the respective three effector sites that will be useful should inhibition become a future focus of our study 12, 13, 27 .
N82A resides in the alanine binding site. This mutation causes reduced PEP affinity even in the absence of effector (left y-intercept of Figure 2 ). Addition of alanine resulted in only a modest increase of inhibition. R501V causes a complete loss of response to the allosteric inhibitor alanine.
Based on previous data 12 , this lack of response is likely due to the inability of the R501V mutant protein to bind Fru-1,6-BP. However, as noted earlier, a lack of response to an effector does not distinguish between whether the effector fails to bind to the mutant protein or if the effector binds, but does not elicit an allosteric response. We previously reported that S12D mimics the quantitatively small, yet well documented, inhibition by protein phosphorylation 13 . Finally, we previously described in vitro evidence for protein oxidation of hLPYK that occurs on Cys436 20 .
Should this oxidation be confirmed as a regulatory mechanism in vivo, then the C436M and C436S mutations will serve to either remove the oxidation, or mimic the oxidation, respectively. These mutations are available for allosterically engineering other regulatory motifs into the enzyme as needed in future studies.
Our long-term goal is to determine if activation of hLPYK is a valid drug target for activating hepatic glycolysis and reducing hepatic glucose production (gluconeogenesis) as a treatment for the hyperglycemia associated with diabetes. Genome-editing the mutations that mimic activation by Fru-1,6-BP (S531E), that prevent inhibition by alanine (H476L), and that prevent inhibition by phosphorylation (S12A) should result in a fully activated enzyme to facilitate the in vivo evaluation of the control of LPYK regulation on hyperglycemia. As anticipated, the triple mutant enzyme binds PEP, even in the absence of effector, similar to the Fru-1,6-BP activated wild-type enzyme. In addition, this modified protein does not respond to either alanine or Fru-1,6-BP. Thus, the triple mutant protein exemplifies an "allosterically engineered" protein that may be useful in an in vivo model to validate hLPYK as an anti-hyperglycemic drug target.
We chose to first test lethality of this fully activated form of the enzyme by expressing a l/r-pyk construct that included the H476L, S531E and S12A mutations in a transgenic mouse line as outlined in Figure 3 . Due to the sequence and size similarity between mouse and human LPYK, western blot analysis did not confirm expression of the transgene protein product. However, these analyses indicated that similar total LPYK protein expression levels were observed in transgenic and wild-type C57BL/6 mice, that is, presence of the transgene did not increase the protein expression level (data not shown). To demonstrate that the transgene protein product was being expressed, we completed a MudPIT Mass spectrometry analysis of liver samples from transgenic mice ( Figure 4) . However, this analysis was challenging given the high sequence similarity between human and mouse LPYK. The protein coded for in the transgene was identified in transgenic mice, but not control mice. The MudPIT evaluation did not show whether the protein products from the transgene and the native pyklr mouse gene are expressed at the same level.
Base on the survival of the transgenic mice, we concluded that expression of the constitutively activated hLPYK subunits was not lethal in vivo. Importantly, the test for lethality was the only reason we created the transgenic mouse line. LPYK is a homotetramer and human and mouse LPYK protein sequences are highly similar. In our design, the triple mutant human LPYK protein is expressed in the presence of expression of the mouse LPYK protein. The fully activated hLPYK protein product from the transgene should be dominant to the wild-type mouse LPYK, which can be inhibited. However, the potential hybrid tetramers between wild-type mouse LPYK subunits and the mutated human LPYK subunits may mask the total activation associated with the human subunits. Therefore, further studies were not pursued with this mouse model. The fact that mutant transgene expression was not lethal provides a way forward for future transgenic and/or genome-edit models to study LPYK function in mouse models.
Discussion
The long-standing tools of the geneticist to knock-out, knock-down and/or overexpress a protein are not useful to evaluate allostery in vivo. Novel methods are needed to verify outcomes of targeting allosteric regulation in vivo. We propose that knocking-in point mutations that mimic allosteric effectors in mice using CRISPR/Cas9 genome-editing may partially fill this need.
Genome-editing will only partially fill the need since constitutive modification of allosteric properties is likely to elicit a compensatory change in gene expression. Therefore, the constitutive nature of genome-edited mutations will not completely mimic the acute response to allosteric effectors. The genome-editing approach we propose requires detailed knowledge about the outcomes of individual mutations on allosteric functions. Although our understanding of allosteric mechanisms lags our understanding of other protein structure/function questions, we demonstrate that we can empirically identify mutations that mimic that results from binding an allosteric effector. Thus, we anticipate that knocking-in mutations in cell culture and animal models will be useful to model potential outcomes from allosteric drugs.
All mutations included in the current work are in one of the regulatory sites of l/r-pyk.
Importantly, each mutation largely modifies only a single type of regulation of the protein. In addition, for mutational mimics, the magnitude of the response (i.e., the extent of change in Kapp-PEP) is like those caused by the respective native allosteric effectors that interact with the wild-type protein. We speculate that these mutations ( Figure 2 ) modify PEP affinity in the active site by preventing or mimicking the respective native allosteric/covalent mechanism. Our H476L/S531E/S12A triple mutant protein data provide evidence that the individual mutations, each with a specific influence on allosteric properties, can be combined to maximize this effect.
This enzyme binds PEP similar to the Fru-1,6-BP activated wild-type protein. Furthermore, it does not respond to either alanine or Fru-1,6-BP addition. Therefore, the triply mutated enzyme is maximally activated and is not further regulated.
Directly transitioning from in vitro protein characterization to developing a mouse model without evaluating the influence of modifications in cell culture is particularly applicable in the study of hLPYK. Even when derived from hepatocarcinomas, cell cultures in general fail to express hLPYK.
The transgenic mouse model created with the triple mutant l/r-pyk gene thrives; expression of the mutant protein does not cause lethality. Live extracts from those mice confirm expression of a modified protein from the transgene. Therefore, the S531E, H476L, and S12A mutations, or combinations of these will be very useful to understand which type of hLPYK regulation is to be targeted for drug design to treat hyperglycemia. These outcomes of this exploratory study support the feasibility of future studies to evaluate if activation of glycolysis in the diabetic liver will be useful to prevent/reduce hepatic glucose production for the treatment of hyperglycemia. chronically activated, PEP will be converted back to pyruvate (Pyr), "outrunning" gluconeogenic reactions that produce glucose (Glc). Pyruvate is then likely to be used in the TCA cycle for generation of ATP energy, which will, in turn, be used to drive the conversion of pyruvate to oxaloacetate (OAA) and OAA to PEP in an energy wasting futile cycle. ; and S12A 20 . Characterization of S12D was previously reported 13 . 
